Powered by LumidaWealth.com
Lumida News
  • Home
  • EarningsNEW
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Macro
    • Markets
    • Real Estate
  • Lifestyle
    • Family Office
    • Health and Longevity
  • Themes
    • Aging & Longevity
    • AI
    • CRE
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
  • About Us
No Result
View All Result
Lumida News
  • Home
  • EarningsNEW
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Macro
    • Markets
    • Real Estate
  • Lifestyle
    • Family Office
    • Health and Longevity
  • Themes
    • Aging & Longevity
    • AI
    • CRE
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
  • About Us
No Result
View All Result
Lumida News
No Result
View All Result
  • Lumida Wealth
  • Lumida Ledger
  • LUMIDA ETF
  • About Us
Home Themes Biotech

Revolutionary Al Model Foresees Dementia Years Ahead

by Team Lumida
June 11, 2024
in Biotech, Health and Longevity
Reading Time: 3 mins read
A A
0
an abstract image of a sphere with dots and lines

Photo by Growtika on Unsplash

Share on TelegramShare on TwitterShare on FacebookShare on LinkedinShare on Whatsapp

Key Takeaways:

  1. New AI model predicts dementia up to 9 years early with 82% accuracy.
  2. Early detection could allow for timely interventions, potentially preventing dementia progression.
  3. Researchers emphasize the need for further validation across diverse populations.

What Happened?

Researchers at Queen Mary University of London developed a new machine learning model that predicts dementia with over 80% accuracy up to nine years before diagnosis. Analyzing 1,111 fMRI scans, the model identifies changes in the brain’s default mode network (DMN), particularly when a person is at rest.

The study, published in Nature Mental Health, included 81 individuals who later developed dementia and 1,030 matched controls. The model accurately predicted dementia within a two-year window before diagnosis.

Why It Matters?

This breakthrough offers a significant advancement in early dementia detection. Early diagnosis could lead to timely interventions, potentially delaying or preventing the onset of dementia.

Dr. Claire Sexton of the Alzheimer’s Association emphasized that Alzheimer’s is linked to decreased functional connectivity within the DMN, aligning with these findings. Early detection is crucial as it provides a chance for interventions before significant cognitive decline occurs.

What’s Next?

Researchers aim to validate the model across more diverse populations and different types of dementia, including frontotemporal and Lewy body dementias. Current limitations include the study’s predominantly white, healthier-than-average cohort.

Neurologists like Clifford Segil stress the need for consistent reproducibility of fMRI results. While no neuroprotective medications are available yet, early detection models like this one could guide future clinical trials, ensuring the right candidates receive new treatments as they emerge.

Source: Medical News Today
Tags: Alzheimer'sDementiafMRIMedical AI
Previous Post

Now Economists Predict Just One Rate Cut This Year

Next Post

Commercial Real Estate: Are Office Spaces the Next Big Financial Risk?

Recommended For You

Dermatology Biotech Bambusa Raises $168.9 Million in an Upsized US IPO at $16 a Share, Valuing It at $815 Million Ahead of Its Nasdaq Debut

by Team Lumida
7 days ago
Biotech Reverse Merger Surge: 6x Jump in 2026 as Startups Exploit Pandemic IPO Hangover; Sophisticated Investors Legitimize Fast-Track Route Over Traditional Listings Despite Dwindling Shell Supply

Bambusa Therapeutics sold 10.556 million shares at $16, the midpoint of its range, and is set to trade on the Nasdaq under the symbol BBTX.

Read more

Moderna and Merck’s Cancer Vaccine Cut Melanoma Recurrence Risk by 42%, and Doctors Call It a Breakthrough Despite the Stock Sell-Off

by Team Lumida
2 weeks ago

Six melanoma specialists call Moderna and Merck’s Phase 3 cancer vaccine data a major advance, even after Moderna shares fell as much as 25% on a data leak.

Read more

Lycia Therapeutics Raised $317.5 Million in an Upsized IPO Priced at the Top of Its Range, Valuing It at $990.6 Million

by Team Lumida
2 weeks ago

Food allergy biotech Lycia sold 17.64 million shares at $18, the top of its range, ahead of its Nasdaq debut on Friday under the symbol LYCA.

Read more

Half of Nasdaq Biotech Stocks Have Under Six Months of Cash, and a 5% 10-Year Yield Is Making Investors Notice

by Team Lumida
2 weeks ago
Biotech Reverse Merger Surge: 6x Jump in 2026 as Startups Exploit Pandemic IPO Hangover; Sophisticated Investors Legitimize Fast-Track Route Over Traditional Listings Despite Dwindling Shell Supply

Biotech stocks have slipped from their August peak as 10-year yields top 5%, with half the sector holding less than six months of cash.

Read more

A 130% Premium Means the Market Valued Silence at Less Than Half What a Buyer Would Pay

by Team Lumida
2 weeks ago
Study Finds Trump’s Drug-Pricing Push Incentivizes Higher Prices and Reduced Access Outside the US

Merck KGaA's new chief executive has now committed $12.4 billion across two debt-funded deals in four months.

Read more

Biotech Reverse Merger Surge: 6x Jump in 2026 as Startups Exploit Pandemic IPO Hangover; Sophisticated Investors Legitimize Fast-Track Route Over Traditional Listings Despite Dwindling Shell Supply

by Team Lumida
3 weeks ago
Biotech Reverse Merger Surge: 6x Jump in 2026 as Startups Exploit Pandemic IPO Hangover; Sophisticated Investors Legitimize Fast-Track Route Over Traditional Listings Despite Dwindling Shell Supply

Biotech reverse mergers: 23 announced 2026 vs 4 in 2025 (6x increase). Also 23 traditional IPOs in 2026. Pandemic IPO bubble (51 in 2020, 70 in 2021) created...

Read more

TRex Bio Seeks $133 Million at a $439 Million Valuation With Lilly Buying In Right Up to the 19.9% Threshold

by Team Lumida
1 month ago
Iambic Therapeutics Files for IPO; Nvidia-Backed AI Drug Discovery Firm Targeting Cancer Treatments; Partners With Abbvie, Takeda; Ticker IAM

Three of the largest pharmaceutical companies sit on the cap table, and the entire valuation rests on one readout due in mid-2027.

Read more

Iambic Therapeutics Files for IPO; Nvidia-Backed AI Drug Discovery Firm Targeting Cancer Treatments; Partners With Abbvie, Takeda; Ticker IAM

by Team Lumida
1 month ago
Iambic Therapeutics Files for IPO; Nvidia-Backed AI Drug Discovery Firm Targeting Cancer Treatments; Partners With Abbvie, Takeda; Ticker IAM

Clinical-stage biotech Iambic Therapeutics (founded 2019, $461.8M raised) files for IPO with Nvidia as shareholder. Uses AI to develop early-stage cancer drugs; partnerships with Abbvie, Takeda, Lundbeck.

Read more

ADARx Seeks $371.9 Million at a $1.74 Billion Valuation With AbbVie Taking 4.9% and Losses Running at $48.4 Million a Half

by Team Lumida
2 months ago
Study Finds Trump’s Drug-Pricing Push Incentivizes Higher Prices and Reduced Access Outside the US

The San Diego siRNA developer prices September 24, backed by a partner that has already paid it $335 million and now anchors the offering.

Read more

Novo Nordisk Disappoints at Capital Markets Day; Plans 5+ Blockbusters by 2035 But Offers No Specific Growth Targets; Shares Fall 7.7%

by Team Lumida
2 months ago
Novo Nordisk Disappoints at Capital Markets Day; Plans 5+ Blockbusters by 2035 But Offers No Specific Growth Targets; Shares Fall 7.7%

Novo targets 150bn DKK ($23bn) pipeline sales by 2035 with 5+ blockbuster launches, but investors wanted more specific growth guidance. Share fell 7.7% on disappointment.

Read more
Next Post
tall trees in front of high-rise buildings

Commercial Real Estate: Are Office Spaces the Next Big Financial Risk?

a close up of the front grill of a car

General Motors Cuts EV Output, Focuses on Shareholders with Massive Buyback

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Related News

US Mortgage Rates Rise to 6.22% After Four Weeks of Declines

US Mortgage Rates Rise to 6.22% After Four Weeks of Declines

November 7, 2025
China’s Bold Economic Moves: What You Need to Know Now

China Signals Major Shift in Inflation Policy as Provinces Lower Price Growth Targets to 2%

January 24, 2025
a car showroom filled with lots of cars

American Car Buyers Finally Push Back on High Prices, Squeezing Automakers and Dealers

December 1, 2025

Subscribe to Lumida Ledger

Browse by Category

  • Lifestyle
    • Family Office
    • Health and Longevity
    • Legacy
    • Next Gen Wealth
    • Trust, Tax, and Estate
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Latest
    • Macro
    • Markets
    • Real Estate
  • Opinions
    • Investing Philosophy
    • Op-Ed
  • Research
    • Trackers
  • Themes
    • Aging & Longevity
    • AI
    • Biotech
    • CRE
    • Cybersecurity
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
    • Software
Facebook Twitter Instagram Youtube TikTok LinkedIn
Lumida News

Premium insights to help you invest beyond the ordinary. Lumida Wealth Management LLC (‘Lumida”) is an SEC registered investment adviser

CATEGORIES

  • Aging & Longevity
  • AI
  • Alt Assets
  • Biotech
  • CRE
  • Crypto
  • Cybersecurity
  • Digital Assets
  • Equities
  • Family Office
  • Health and Longevity
  • Investing Philosophy
  • Latest
  • Legacy
  • Legacy Brands
  • Lifestyle
  • Macro
  • Markets
  • News
  • Next Gen Wealth
  • Nuclear Renaissance
  • Op-Ed
  • Private Credit
  • Real Estate
  • Software
  • Themes
  • Trackers
  • Trust, Tax, and Estate

BROWSE BY TAG

AI AI chips Amazon Apple Artificial Intelligence Banking Bank of America China Commercial Real Estate CPI data centers Donald Trump EARNINGS ELON MUSK Federal Reserve financial services generative AI Goldman Sachs Google India Inflation Interest Rates Investment Strategy Japan Jerome Powell JPMorgan Markets Meta Microsoft Nasdaq Novo Nordisk Nuclear Energy Nvidia oil OpenAI private equity S&P 500 SEC Semiconductor stock market stock surge Tech Stocks tesla Trump Whale Watch

© 2025 Lumida Wealth Management LLC is an SEC registered investment adviser. Privacy Policy. Cookies Policy.
Disclaimer Important Information This site is for informational purposes only. Information presented on this site does not constitute as investment advice.

Lumida Wealth Management LLC (‘Lumida”) is an SEC registered investment adviser. SEC registration does not constitute an endorsement of the firm by the Commission nor does it indicate that the adviser has attained a particular level of skill or ability.

Lumida's website (referred to herein as the "Website") is limited to the dissemination of general information pertaining to its advisory services, together with access to additional investment-related information, publications, and links. Accordingly, the publication of the Website on the Internet should not be construed by any client and/or prospective client Lumida’s solicitation to effect, or attempt to effect transactions in securities, or the rendering of personalized investment advice for compensation, over the Internet.

Any subsequent, direct communication by Lumida with a prospective client will be conducted by a representative that is either registered or qualifies for an exemption or exclusion from registration in the state where the prospective client resides.

‍Lead Capture Forms: By submitting your contact information in the forms on this site, you are not obligated to invest in Lumida's product or services.
‍Address: Lumida Wealth Management, 25 W 39th Street Suite 700, New York, NY 10018

No Result
View All Result
  • Home
  • Earnings
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Macro
    • Markets
    • Real Estate
  • Lifestyle
    • Family Office
    • Health and Longevity
  • Themes
    • Aging & Longevity
    • AI
    • CRE
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
  • About Us

© 2025 Lumida Wealth Management LLC is an SEC registered investment adviser. Privacy Policy. Cookies Policy.
Disclaimer Important Information This site is for informational purposes only. Information presented on this site does not constitute as investment advice.

Lumida Wealth Management LLC (‘Lumida”) is an SEC registered investment adviser. SEC registration does not constitute an endorsement of the firm by the Commission nor does it indicate that the adviser has attained a particular level of skill or ability.

Lumida's website (referred to herein as the "Website") is limited to the dissemination of general information pertaining to its advisory services, together with access to additional investment-related information, publications, and links. Accordingly, the publication of the Website on the Internet should not be construed by any client and/or prospective client Lumida’s solicitation to effect, or attempt to effect transactions in securities, or the rendering of personalized investment advice for compensation, over the Internet.

Any subsequent, direct communication by Lumida with a prospective client will be conducted by a representative that is either registered or qualifies for an exemption or exclusion from registration in the state where the prospective client resides.

‍Lead Capture Forms: By submitting your contact information in the forms on this site, you are not obligated to invest in Lumida's product or services.
‍Address: Lumida Wealth Management, 25 W 39th Street Suite 700, New York, NY 10018